252 results on '"Rimondi, Erika"'
Search Results
2. Role of vitamin D in the pathogenesis of atheromatosis
3. Metabolic Syndrome and Psoriasis: Pivotal Roles of Chronic Inflammation and Gut Microbiota.
4. Classical and Innovative Evidence for Therapeutic Strategies in Retinal Dysfunctions
5. Factors Predictive of Double Anterior Chamber Formation Following Deep Anterior Lamellar Keratoplasty
6. Effects of intermittent pneumatic compression treatment on clinical outcomes and biochemical markers in patients at low mobility with lower limb edema
7. Lower maternal serum tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in early preeclampsia. A retrospective study
8. P1295: ADVANTAGE OF FIRST-LINE TDM-DRIVEN USE OF INFLIXIMAB FOR TREATING ACUTE INTESTINAL AND LIVER GVHD IN CHILDREN: A PROSPECTIVE, SINGLE-CENTER STUDY.
9. P1272: DEFIBROTIDE IMPACT ON THE ACUTE GRAFT-VERSUS-HOST DISEASE INCIDENCE IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS.
10. Advantage of First-Line Therapeutic Drug Monitoring-Driven Use of Infliximab for Treating Acute Intestinal and Liver GVHD in Children: A Prospective, Single-Center Study
11. Convolvulus pluricaulis Choisy’s Extraction, Chemical Characterization and Evaluation of the Potential Effects on Glycaemic Balance in a 3T3-L1 Adipocyte Cell Model
12. Supplementary Methods from C-Reactive Protein Downregulates TRAIL Expression in Human Peripheral Monocytes via an Egr-1–Dependent Pathway
13. Defibrotide impact on the acute GVHD disease incidence in pediatric hematopoietic stem cell transplant recipients
14. Mitochondria-Targeted Antioxidants, an Innovative Class of Antioxidant Compounds for Neurodegenerative Diseases: Perspectives and Limitations
15. The role of the mTOR pathway in diabetic retinopathy
16. Prenylation Defects and Oxidative Stress Trigger the Main Consequences of Neuroinflammation Linked to Mevalonate Pathway Deregulation
17. Acute Neurological Involvement after Donor Lymphocyte Infusion for Post-Transplant Viral Infection: The Same Pattern of Novel Cancer Immunotherapy-Related CNS Toxicity?
18. New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib
19. Human Lymphatic Endothelial Glycocalyx-like Structure Electron Microscopy and Immunohistochemistry Identification
20. Synthesis and Biological Investigation of Bile Acid-Paclitaxel Hybrids
21. Autoinflammatory Diseases and Cytokine Storms—Imbalances of Innate and Adaptative Immunity
22. Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism
23. Sorafenib inhibits in vitro osteoclastogenesis by down-modulating Mcl-1
24. Mevalonate Kinase Deficiency and Squalene Synthase Inhibitor (TAK-475): The Balance to Extinguish the Inflammation
25. Overcoming of Microenvironment Protection on Primary Chronic Lymphocytic Leukemia Cells after Treatment with BTK and MDM2 Pharmacological Inhibitors
26. Hydrogen sulfide down-regulates the expression and release of osteoprotegerin (OPG) by vascular endothelial cells
27. Pegylated TRAIL retains anti-leukemic cytotoxicity and exhibits improved signal transduction activity with respect to TRAIL
28. Perifosine selectively induces cell cycle block and modulates retinoblastoma and E2F1 protein levels in p53 mutated leukemic cell lines
29. Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells
30. MitoQ Is Able to Modulate Apoptosis and Inflammation
31. Levels of TNF-Related Apoptosis-Inducing Ligand (TRAIL) Show a Long-term Stability in the Breast Milk of Mothers of Preterm Infants
32. Human Colostrum and Breast Milk Contain High Levels of TNF-Related Apoptosis-Inducing Ligand (TRAIL)
33. miRNAs as Influencers of Cell–Cell Communication in Tumor Microenvironment
34. Soluble TRAIL does not impair the anti-osteoclastic activity of osteoprotegerin
35. TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF
36. Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells
37. TRAIL Activates a Caspase 9/7-Dependent Pathway in Caspase 8/10-Defective SK-N-SH Neuroblastoma Cells with Two Functional End Points: Induction of Apoptosis and PGE2 Release
38. New biomarkers and therapeutic strategies in acute lymphoblastic leukemias: Recent advances
39. TRAIL, OPG, and TWEAK in kidney disease: biomarkers or therapeutic targets?
40. New biomarkers and therapeutic strategies in acute lymphoblastic leukemias: Recent advances.
41. A novel endovenous scaffold for the treatment of chronic venous obstruction in a porcine model: Histological and ultrastructural assessment
42. Relationship between low levels of circulating TRAIL and atheromatosis progression in patients with chronic kidney disease
43. Venous compliance and clinical implications
44. Expeditious Synthesis and Biological Characterization of Enantio‐Enriched (‐)‐Nutlin‐3
45. The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells
46. A novel endovenous scaffold for the treatment of chronic venous obstruction in a porcine model: Histological and ultrastructural assessment.
47. MDM2 antagonist nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts via a p53-dependent pathway
48. Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia
49. Metformin combined with sodium dichloroacetate promotes B leukemic cell death by suppressing anti-apoptotic protein Mcl-1
50. Serum Soluble Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Levels in Older Subjects with Dementia and Mild Cognitive Impairment
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.